Cas:29113-34-6 4-oxo-1H-quinazoline-2-carboxylic acid manufacturer & supplier

Chemical Name:4-oxo-1H-quinazoline-2-carboxylic acid

CAS.NO:29113-34-6

Synonyms:4-Quinazolone-2-carboxylic Acid;4-oxo-3,4-dihydroquinazoline-2-carboxylic acid;3,4-dihydro-4-oxoquinazoline-2-carboxylic acid;4-Oxo-3,4-dihydro-chinazolin-2-carbonsaeure;Chinazol-4-on-2-carbonsaeure;quinazolone-2-carboxylic acid;4-Quinazolone-2-carboxylic Acid;4-Chinazolon-2-carbonsaeure

Molecular Formula:C₉H₆N₂O₃

Molecular Weight:190.15600

HS Code:

Physical and Chemical Properties:

Melting point:N/A

Boiling point:427.6ºC at 760 mmHg

Density:1.56g/cm3

Index of Refraction:1.71

PSA:83.05000

Exact Mass:190.03800

LogP:0.62130

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 4-Quinazolone-2-carboxylic Acid chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Chinazolon-2-carbonsaeure physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3,4-dihydro-4-oxoquinazoline-2-carboxylic acid Use and application,3,4-dihydro-4-oxoquinazoline-2-carboxylic acid technical grade,usp/ep/jp grade.

Related News: The iLet is designed to function as three medical devices in one. It can be configured as an insulin-only bionic pancreas, a glucagon-only bionic pancreas, or a bihormonal bionic pancreas using insulin and glucagon. 4-oxo-1H-quinazoline-2-carboxylic acid manufacturer Both patients were being treated in isolation units at a Manila hospital. 4-oxo-1H-quinazoline-2-carboxylic acid supplier In the TOP50 list of API export companies in 2017, the geographical clustering of advantageous companies is still obvious. For example, Huahai and Pluo in Zhejiang, CSPC of Hebei, Xinhua Pharmaceutical and Xinfa Pharmaceutical of Shandong rank well. Rank. 4-oxo-1H-quinazoline-2-carboxylic acid vendor In the TOP50 list of API export companies in 2017, the geographical clustering of advantageous companies is still obvious. For example, Huahai and Pluo in Zhejiang, CSPC of Hebei, Xinhua Pharmaceutical and Xinfa Pharmaceutical of Shandong rank well. Rank. 4-oxo-1H-quinazoline-2-carboxylic acid factory The rigosertib Pre-approval Access Program is expected to launch in first half of 2020 and will allow Inceptua to supply intravenous rigosertib within designated countries, primarily and initially concentrated in selected countries in Europe, in response to physician requests for patients with higher-risk MDS who have exhausted all available treatment options, and are not eligible for or have no access to the INSPIRE study.